Dr. Annet Kirabo, D.V.M., Ph.D., FAHA, a professor of medicine at Vanderbilt Health, has been named the recipient of the 2026 Joseph A. Vita Award by the American Heart Association (AHA). The award recognizes her groundbreaking discoveries linking immune activation and inflammation to high blood pressure, a finding that has reshaped cardiovascular science. She will receive the honor during the Opening Session of the AHA's Scientific Sessions 2026, held Nov. 6-9 in Chicago, a premier global exchange of cardiovascular research and clinical updates.
The Joseph A. Vita Award, named after the late founding editor of the Journal of the American Heart Association (JAHA), is presented annually to a scientist whose research has significantly advanced cardiovascular biology or health within the past five years and has been published in AHA journals. The recipient is selected by the editors-in-chief of the Association's 14 peer-reviewed journals and celebrates work that transforms or changes the direction of cardiovascular science.
Dr. Kirabo's research demonstrated that lipid oxidation-derived protein adducts act as neoantigens, triggering antigen-presenting cell activation, T-cell responses, vascular dysfunction, and hypertension. This paradigm-shifting discovery fundamentally changed the understanding of how the immune system contributes to blood pressure regulation. Her laboratory now combines immunology, vascular biology, genomics, metabolomics, and single-cell technologies to identify new therapeutic strategies for cardiovascular and kidney disease, with potential to transform patient care.
"Dr. Annet Kirabo exemplifies the spirit of the Joseph A. Vita Award," said Manesh R. Patel, M.D., FAHA, the AHA's 2026-2027 volunteer president. "Her pioneering discoveries represent a paradigm shift in cardiovascular biology, reshaping our understanding of hypertension by revealing how immune activation and inflammation drive cardiovascular disease."
Beyond her scientific achievements, Dr. Kirabo has been an active AHA volunteer since 2009, serving on the Council on Hypertension Communications Committee and the Council Operations Committee. She has been on the editorial board of the Hypertension journal since 2018 and an associate editor of Circulation Research since 2019. Her commitment to mentorship has trained dozens of graduate students and early-career investigators, many of whom have gone on to faculty positions.
Dr. Kirabo's work has far-reaching implications for the millions affected by hypertension, a leading risk factor for heart disease and stroke. By uncovering immune mechanisms, her research opens new avenues for preventing and treating these conditions. The recognition underscores the importance of continued investment in cardiovascular research, which could lead to novel therapies and improved outcomes worldwide. Additional multimedia is available on the right column of the release link, and more information about the AHA can be found at heart.org.
